BridgeBio Oncology Therapeutics (BBOT) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on BridgeBio Oncology Therapeutics (BBOT) is Moderate Underperform.

The composite score behind that read is -0.33, weighing +0.69 of bullish evidence against -0.36 bearish.

BridgeBio Oncology Therapeutics last closed at $3.60, -7.46% on the session.

Against the IVW growth benchmark the position is -8.38% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

16 graded predictions for BBOT so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks BridgeBio Oncology Therapeutics in the 19th percentile on return on equity, where 100 is best.

BridgeBio Oncology Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $311.88M.

StockMap tracks BridgeBio Oncology Therapeutics as the 195th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite BridgeBio Oncology Therapeutics ranks 266th of 344 in the group, against a group median of -0.21.